Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients

Abstract Kidney transplant recipients are at an increased risk of severe COVID-19-associated hospitalisation and death. Vaccination has been a key public health strategy to reduce disease severity and infectivity, but the effectiveness of COVID vaccines is markedly reduced in kidney transplant recip...

Descrición completa

Detalles Bibliográficos

Principais autores:	Matthew Tunbridge, Griffith B. Perkins, Julian Singer, Tania Salehi, Tracey Ying, Branka Grubor-Bauk, Simon Barry, Beatrice Sim, Pravin Hissaria, Steven J. Chadban, P. Toby Coates
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2022-09-01
Series:	Trials
Assuntos:	Kidney transplantation Randomised controlled trial Sirolimus Immunosuppression SARS-CoV-2 COVID-19
Acceso en liña:	https://doi.org/10.1186/s13063-022-06634-w
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!